In addition to being Head of Scientific Evaluation at Advent Life Sciences he is also CEO of Advent portfolio company Pheno Therapeutics. He was most recently Chief Executive Officer of Pandeia Therapeutics which was acquired by a mid-cap pharmaceutical company in December 2022.

Prior to this he was Chief Scientific Officer of Chronos Therapeutics and Chief Executive Officer of Polleo Pharma. Fraser has co-founded 5 biotech companies and consulted for multiple startups and venture capital firms since leaving a career in big pharma. Fraser began his career as a scientist at Merck’s Neuroscience Research Centre in the UK before moving on to roles at Astra Zeneca and Shire where he headed discovery biology for Speciality Pharmaceuticals. Fraser studied Immunology and Pharmacology at the University of Strathclyde and undertook a PhD in Neuropharmacology at the School of Pharmacy, University of London. He later studied for an executive MBA at Alliance Manchester Business School.